---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-018409"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T19:34:49.266712+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amylyx reports FY 2023 net income $49.3M vs loss; product revenue $380.8M

## Summary
- Full-year 2023 net product revenue $380.8M; Q4 revenue $108.4M vs $102.7M in Q3 2023.
- Net income of $49.3M (diluted EPS $0.70) for 2023 vs net loss of $198.4M ($3.39 loss per share) in 2022.
- Cash, cash equivalents and short-term investments of $371.4M at Dec 31, 2023 vs $355.0M at Sep 30, 2023.
- Phase 3 PHOENIX trial topline data expected Q1/Q2 2024; Phase 3 ORION trial dosed first patient Dec 2023, data 2025-2026.
- Appointed Camille Bedrosian CMO, Linda Arsenault CHRO, Dan Monahan GM & Head of U.S. Commercial in late 2023/early 2024.

## SEC filing metadata
- accession: 0000950170-24-018409
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000095017024018409/0000950170-24-018409-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000095017024018409/amlx-20240222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-018409
- JSON: https://secwatch.observer/filing/0000950170-24-018409.json
- Plain text: https://secwatch.observer/filing/0000950170-24-018409.txt

## Key facts
- Earnings Releases
  Amylyx Pharmaceuticals, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $108.4 million, net income $4.7 million.
  - Period: the fourth quarter ended December 31, 2023
  - Revenue: $108.4 million
  - Net income: $4.7 million
  - Result: reported results
  source text: • Reported $380.8 million in net product revenue for the full year 2023, including $108.4 million in the fourth quarter • Delivered $49.3 million in net income for the full year 2023, including $4.7 million in the fourth quarter
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658551/000095017024018409/0000950170-24-018409-index.htm
- Earnings Releases
  Amylyx Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: revenue $380.8 million, net income $49.3 million.
  - Period: the fiscal year ended December 31, 2023
  - Revenue: $380.8 million
  - Net income: $49.3 million
  - Result: reported results
  source text: • Reported $380.8 million in net product revenue for the full year 2023, including $108.4 million in the fourth quarter • Delivered $49.3 million in net income for the full year 2023, including $4.7 million in the fourth quarter
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658551/000095017024018409/0000950170-24-018409-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.